Here are the DEF 14A proxy statements from Bicara Therapeutics Inc. (BCAX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow BCAX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAX filings page.
Bicara Therapeutics Inc. will hold its 2026 annual stockholder meeting virtually on June 9, 2026, with a record date of April 15, 2026. Stockholders will vote on electing two Class II directors to terms ending in 2029 and ratifying KPMG LLP as independent auditor for 2026.
The board will shrink from ten to nine members, with director Nils Lonberg, Ph.D., not standing for re-election. Bicara describes its board committee structure, director independence, and nomination process, and outlines cash retainers and option grants for non-employee directors and 2025 compensation for key executives.